Auditory MMN EEG in TRD in Response to Ketamine

Unity Health Toronto30 enrolled

Overview

To develop and test a neurocomputational model of ketamine treatment response predictions in TRD.

The investigators propose applying a previously validated computational model of the MMN and the ensuing effects of NMDAR antagonism to predict treatment response following ketamine infusions in TRD patients and distinguish ketamine's antisuicidal effects from those related to mood improvements. The study has two subgoals: first, the computational mechanisms underlying MMN reductions that predict ketamine treatment response in TRD patients will be examined. Second, the computational mechanisms will be linked to their underlying neural causes using neural circuit models. Beyond understanding ketamine's short- and long-term mechanisms of action in TRD, the parameters obtained from fitting these models to noninvasive EEG recordings may facilitate single-patient treatment predictions. If successful, this approach may provide clinically useful prognostic statements in individual patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Treatment-resistant Depression (TRD)

Interventions

KetamineDRUG

Participants suffering from TRD will receive their ketamine treatment intravenously twice weekly for two weeks (4 treatments in total). A dose of 0.5 mg/kg is infused over 40 minutes, with dose adjustments made at the psychiatrist's discretion.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1.18 to 65 years of age 2. Meeting Diagnostic and Statistical Manual for Mental Disorders (DSM-5) criteria for MDD and in a Major Depressive Episode and ≥10 on the Montgomery-Asberg Depression Rating Scale (MADRS). 3\. Competent to consent-based on their ability to provide a spontaneous narrative description of the key elements of the study. 4\. Failure of at least two trials of antidepressant therapy during the current episode (treatment-resistant depression) and receiving ketamine treatment clinically as administered by their clinician 5. Staying on stable dosages of any concomitant psychotropic medications. Exclusion Criteria: 1. History of bipolar disorder or psychosis 2. Current substance use or history of substance use during the past year (excluding nicotine and caffeine use disorder) 3. Concomitant major and unstable medical or neurologic illness or a history of seizures. 4. Non-English-speaking individuals.

Locations (1)

St. Michael's Hospital

Toronto, Ontario, Canada

RECRUITING

Outcomes

Primary Outcomes

Clinical remission

Remission, defined as MADRS \<10, and suicide risk reduction is defined as a ≥ 50% reduction in the suicidal ideation item of the MADRS scale from baseline

Time frame: 4 weeks following the baseline visit

Secondary Outcomes

Modelling

Modelling the underlying cognitive and behavioural mechanisms to their neural causes from the effect of ketamine on TRD patients

Time frame: 2 weeks following the baseline visit

Central Contacts

Venkat Bhat, MD MSc

CONTACT

416-360-4000 Venkat.Bhat@unityhealth.to

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.